Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websiteastellasventure.com
Employees
Founded9/2005
DescriptionCorporate venture capital

Funds

Offices

Office
2180 Sand Hill Road
Suite 460
Menlo Park, CA, 94025
USA

People

President & Chief Executive Officer
Associate Investment Director
Associate Investment Director
Senior Investment Director
Investment Director
Investment Director

Tags

Astellas Venture Management

Astellas Venture Management is a financial organisation which targets its investments in the biotechnologies.

They invest in companies that are dedicated to developing new pharmaceutical seeds, or constructing a new drug discovery platform. Their investments are not limited to any geographical location.

Recent Milestones

Investments

Company Date Round Size Participants
Crescendo Biologics 4/2014Series A£2M4
Crescendo Biologics 12/2013Series A£17.5M3
Effector Therapeutics 5/2013Venture Round$45M7
DecImmune Therapeutics 2/2013Private Equity$2.25M3
Bicycle Therapeutics 12/2012Venture Round£3.75M5
F2G 9/2012Venture Round$30M6
PhaseBio Pharmaceuticals 6/2012Series B$23M5
Cleave Biosciences 10/2011Series A$44M6
Verastem 7/2011Series B$32M6
Fate Therapeutics 5/2011Series B$36M6
DecImmune Therapeutics 9/2010Venture Round$3.2M3
Nereus Pharmaceuticals 6/2010Series E$20M7
Epizyme 10/2009Series B$32M5
Viamet Pharmaceuticals 7/2009Series B$25M6
Intradigm Corporation 1/2009Series B$21.4M8
F2G 8/2008Venture Round£6.3M4
Inimex Pharmaceuticals 6/2008Series B$22M8
Lectus Therapeutics 2/2006Series A£8.2M4

Videos

Sources

  1. Crescendo Biologics Raises Further £2M in Series A Financing (finsmes.com) [edit]
  2. Crescendo Biologics Raises £17.5M in Series A Financing (finsmes.com) [edit]
  3. Effector Therapeutics snags $45M venture round from A-list backers (fiercebiotech.com) [edit]
  4. DecImmune Therapeutics Completes $2.25M Equity Financing (finsmes.com) [edit]
  5. Bicycle Therapeutics Raises £3.75M in Funding (finsmes.com) [edit]
  6. F2G Ltd Completes $30 Million Financing Round to Fund Pre-clinical and Clinical Development of Novel Anti-fungal Compounds (fiercebiotech.com) [edit]
  7. PhaseBio Pharmaceuticals Books $23M in Third Tranche of Series B (pevc.dowjones.com) [edit]
  8. Cleave Biosciences Raises $42M in Series A Financing (finsmes.com) [edit]
  9. Verastem rounds up $32M in second funding (masshightech.com) [edit]
  10. SEC (sec.gov) [edit]
  11. DecImmune Therapeutics Receives $1M in Equity Financing; $2.2M Phase II SBIR Funding (finsmes.com) [edit]
  12. Nereus Pharmaceuticals, Inc.: Series E $20M (onbiovc.com) [edit]
  13. Epizyme pulls in $32M in VC capital, new investors (fiercebiotech.com) [edit]
  14. SEC (sec.gov) [edit]
  15. Intradigm Corporation Closes Final Tranche of $21.4 Million Series B Financing; Philip Haworth, Ph.D. Appointed Chief Executive (fiercebiotech.com) [edit]
  16. F2G Ltd completes £6.3million financing round to fund pre-clinical and clinical development (f2g.com) [edit]
  17. Capital Funding Report [edit]
  18. Lectus Therapeutics closes Series A funding round raising £8.2 million (lectustherapeutics.com) [edit]
Edit This Page
Last Edited 4/15/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy